Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease - PubMed (original) (raw)

. 2006 Sep;31(9):1153-62.

doi: 10.1007/s11064-006-9140-9. Epub 2006 Sep 1.

Affiliations

• PMID: 16947080
• DOI: 10.1007/s11064-006-9140-9

Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease

Pravat K Mandal et al. Neurochem Res. 2006 Sep.

Erratum in

• Neurochem Res. 2007 Nov;32(11):2002

Abstract

Amyloidogenic proteins (Abeta peptide) in Alzheimer's disease (AD) and alpha-synuclein (alpha-Syn) in Parkinson's disease (PD) are typically soluble monomeric precursors, which undergo remarkable conformational changes and culminate in the form of aggregates in diseased condition. Overlap of clinical and neuropathological features of both AD and PD are observed in dementia with Lewy body (DLB) disease, the second most common form of dementia after AD. The identification of a 35-amino acid fragment of alpha-Syn in the amyloid plaques in DLB brain have raised the possibility that Abeta and alpha-Syn interact with each other. In this report, the molecular interaction of alpha-Syn with Abeta40 and/or Abeta42 are investigated using multidimensional NMR spectroscopy. NMR data in the membrane mimic environment indicate specific sites of interaction between membrane-bound alpha-Syn with Abeta peptide and vice versa. These Abeta-alpha-Syn interactions are demonstrated by reduced amide peak intensity or change in chemical shift of amide proton of the interacting proteins. Based on NMR results, the plausible molecular mechanism of overlapping pathocascade of AD and PD in DLB due to interactions between alpha-Syn and Abeta is described. To the best of our knowledge, it is the first report using multidimensional NMR spectroscopy that elucidates molecular interactions between Abeta and alpha-Syn which may lead to onset of DLB.

PubMed Disclaimer

Comment in

Similar articles

• Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.
  Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C, Colloby SJ, Jellinger K, Attems J. Walker L, et al. Acta Neuropathol. 2015 May;129(5):729-48. doi: 10.1007/s00401-015-1406-3. Epub 2015 Mar 11. Acta Neuropathol. 2015. PMID: 25758940
• Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
  Vaikath NN, Majbour NK, Paleologou KE, Ardah MT, van Dam E, van de Berg WD, Forrest SL, Parkkinen L, Gai WP, Hattori N, Takanashi M, Lee SJ, Mann DM, Imai Y, Halliday GM, Li JY, El-Agnaf OM. Vaikath NN, et al. Neurobiol Dis. 2015 Jul;79:81-99. doi: 10.1016/j.nbd.2015.04.009. Epub 2015 Apr 30. Neurobiol Dis. 2015. PMID: 25937088
• Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
  Jellinger KA. Jellinger KA. J Neural Transm (Vienna). 2018 Apr;125(4):615-650. doi: 10.1007/s00702-017-1821-9. Epub 2017 Dec 8. J Neural Transm (Vienna). 2018. PMID: 29222591 Review.
• Associations Between APOE Variants, Tau and α-Synuclein.
  Rodriguez-Vieitez E, Nielsen HM. Rodriguez-Vieitez E, et al. Adv Exp Med Biol. 2019;1184:177-186. doi: 10.1007/978-981-32-9358-8_15. Adv Exp Med Biol. 2019. PMID: 32096038 Review.

Cited by

• Pathologic subtyping of Alzheimer's disease brain tissue reveals disease heterogeneity.
  Lam TG, Ross SK, Ciener B, Xiao H, Flaherty D, Lee AJ, Dugger BN, Reddy H, Teich AF. Lam TG, et al. medRxiv [Preprint]. 2024 Oct 15:2024.10.14.24315458. doi: 10.1101/2024.10.14.24315458. medRxiv. 2024. PMID: 39484271 Free PMC article. Preprint.
• High Levels of _β_-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse.
  Piccarducci R, Pietrobono D, Pellegrini C, Daniele S, Fornai M, Antonioli L, Trincavelli ML, Blandizzi C, Martini C. Piccarducci R, et al. Oxid Med Cell Longev. 2019 Jun 9;2019:5030475. doi: 10.1155/2019/5030475. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 31281579 Free PMC article.
• Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro.
  Köppen J, Schulze A, Machner L, Wermann M, Eichentopf R, Guthardt M, Hähnel A, Klehm J, Kriegeskorte MC, Hartlage-Rübsamen M, Morawski M, von Hörsten S, Demuth HU, Roßner S, Schilling S. Köppen J, et al. Molecules. 2020 Jan 29;25(3):580. doi: 10.3390/molecules25030580. Molecules. 2020. PMID: 32013170 Free PMC article.
• α-synuclein-assisted oligomerization of β-amyloid (1-42).
  Chau E, Kim JR. Chau E, et al. Arch Biochem Biophys. 2022 Mar 15;717:109120. doi: 10.1016/j.abb.2022.109120. Epub 2022 Jan 15. Arch Biochem Biophys. 2022. PMID: 35041853 Free PMC article.
• Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease.
  Swirski M, Miners JS, de Silva R, Lashley T, Ling H, Holton J, Revesz T, Love S. Swirski M, et al. Alzheimers Res Ther. 2014 Dec 1;6(5-8):77. doi: 10.1186/s13195-014-0077-y. eCollection 2014. Alzheimers Res Ther. 2014. PMID: 25452767 Free PMC article.

References

1. 1. J Magn Reson. 2011 Dec;213(2):357-63 - PubMed
2. 1. J Biol Chem. 2005 Jun 17;280(24):22670-8 - PubMed
3. 1. Nature. 1997 Aug 28;388(6645):839-40 - PubMed
4. 1. J Neurol Neurosurg Psychiatry. 1989 Feb;52(2):185-92 - PubMed
5. 1. J Mol Biol. 1999 Jan 15;285(2):755-73 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal